• 1
    Bennett JM,Komrokji R,Kouides P. The myelodysplastic syndromes. In: Abeloff MD, Armitage JO, Niederhuber JE, editors. Clincial Oncology. New York: Churchill Livingstone; 2004. pp 28492881.
  • 2
    Bennett JM,Komrokji RS. The myelodysplastic syndromes: Diagnosis, molecular biology and risk assessment. Hematology 2005; 10 Suppl 1: 258269.
  • 3
    Epling-Burnette PK,List AF. Advancements in the molecular pathogenesis of myelodysplastic syndrome. Curr Opin Hematol 2009; 16: 7076.
  • 4
    Greenberg P,Cox C,LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 20792088.
  • 5
    Della Porta MG,Malcovati L,Strupp C, et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica 2011; 96: 441449.
  • 6
    Greipp PR,San Miguel J,Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 34123420.
  • 7
    Lai CC,You JF,Yeh CY, et al. Low preoperative serum albumin in colon cancer: a risk factor for poor outcome. Int J Colorectal Dis 2011; 26: 473481.
  • 8
    Sirott MN,Bajorin DF,Wong GY, et al. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer 1993; 72: 30913098.
  • 9
    Kharfan-Dabaja MA,Chavez JC,Yu D, et al. Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 2011; 17: 384393.
  • 10
    Komrokji RS,Kharfan-Dabaja MA,Price SL, et al. Albumin is a prognostic factor for response and overall survival in relapsed or refractory acute myeloid leukemia (AML). ASH Annual Meeting Abstracts 2009; 114: 4685.
  • 11
    Kantarjian H,O'Brien S,Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008; 113: 13511361.
  • 12
    Malcovati L,Germing U,Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007; 25: 35033510.
  • 13
    Della Porta MG,Malcovati L,Boveri E, et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol 2009; 27: 754762.
  • 14
    Neumann F,Gattermann N,Barthelmes H-U, et al. Levels of beta 2 microglobulin have a prognostic relevance for patients with myelodysplastic syndrome with regard to survival and the risk of transformation into acute myelogenous leukemia. Leuk Res 2009; 33: 232236.
  • 15
    Sanz G,Nomdedeu B,Such E, et al. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome. ASH Annual Meeting Abstracts 2008; 112: 640.
  • 16
    Wimazal F,Sperr WR,Kundi M, et al. Prognostic significance of serial determinations of lactate dehydrogenase (LDH) in the follow-up of patients with myelodysplastic syndromes. Ann Oncol 2008; 19: 970976.
  • 17
    Dunbar AJ,Gondek LP,O'Keefe CL, et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res 2008; 68: 1034910357.
  • 18
    Gelsi-Boyer V,Trouplin V,Roquain J, et al. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol 2010; 151: 365375.
  • 19
    Kosmider O,Gelsi-Boyer V,Cheok M, et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood 2009; 114: 32853291.
  • 20
    Owen WF,Lew NL,Liu Y, et al. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993; 329: 10011006.
  • 21
    Bommert K,Bargou RC,Stühmer T. Signalling and survival pathways in multiple myeloma. Eur J Cancer 2006; 42: 15741580.
  • 22
    Brenner DA,Buck M,Feitelberg SP, et al. Tumor necrosis factor-alpha inhibits albumin gene expression in a murine model of cachexia. J Clin Investig 1990; 85: 248255.
  • 23
    Feng X,Scheinberg P,Wu CO, et al. Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes. Haematologica 2011; 96: 602606.